Late relapse of non-seminomatous testicular cancer during treatment of multiple sclerosis with interferon β-1a: A case report
- PMID: 25289098
- PMCID: PMC4186558
- DOI: 10.3892/ol.2014.2519
Late relapse of non-seminomatous testicular cancer during treatment of multiple sclerosis with interferon β-1a: A case report
Abstract
Germ cell tumors (GCTs) comprise 95% of malignant tumors arising in the testes. The present study reports a patient diagnosed with non-seminomatous testicular cancer, stage IB, with a good risk prediction according to the International Germ Cell Cancer Collaborative Group classification. The patient received chemotherapy with bleomycin, etoposide and cisplatin, and achieved complete remission. Eleven years later, while receiving treatment with interferon β-1a for multiple sclerosis, the patient developed a relapse of the original cancer in the lungs and lymph nodes. The majority of GCTs relapse within the first two years of treatment, while 2-4% of patients can present with late relapses. There is no clear established association between multiple sclerosis and testicular cancer; we present the hypothesis that the inmunosupressor treatment that was administered for the multiple sclerosis promoted the cancer relapse.
Keywords: inmunosupression; late relapse; multiple sclerosis; non-seminomatous germ cell tumor; β-interferon.
Similar articles
-
A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors.Ann Oncol. 1996 Dec;7(10):1015-21. doi: 10.1093/oxfordjournals.annonc.a010493. Ann Oncol. 1996. PMID: 9037359 Clinical Trial.
-
Late relapse of germ cell tumors after cisplatin-based chemotherapy.Ann Oncol. 1997 Jan;8(1):41-7. doi: 10.1023/a:1008253323854. Ann Oncol. 1997. PMID: 9093706 Review.
-
Prostatic relapse of an undifferentiated teratoma 24 years after orchidectomy.BMC Res Notes. 2015 Oct 1;8:524. doi: 10.1186/s13104-015-1445-9. BMC Res Notes. 2015. PMID: 26428307 Free PMC article.
-
Late relapses (>2 years) in patients with stage I testicular germ cell tumors: predictive factors and survival.Urol Oncol. 2013 May;31(4):499-504. doi: 10.1016/j.urolonc.2011.06.001. Epub 2011 Jul 30. Urol Oncol. 2013. PMID: 21803619
-
[Urologic treatment of testicular germ cell cancer].Arch Esp Urol. 2002 Oct;55(8):927-36. Arch Esp Urol. 2002. PMID: 12455283 Review. Spanish.
Cited by
-
Adverse side effects of Glatiramer acetate and Interferon beta-1a in patients with multiple sclerosis: A systematic review of case reports.Curr J Neurol. 2023 Apr 4;22(2):115-136. doi: 10.18502/cjn.v22i2.13340. Curr J Neurol. 2023. PMID: 38011449 Free PMC article.
References
-
- Motzer RJ, Agarwal N, Beard C, et al. NCCN clinical practice guidelines in oncology: testicular cancer. J Natl Compr Canc Netw. 2009;10:672–693. - PubMed
-
- Lebrun C, Debouverie M, Vermersch P, et al. Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. Mult Scler. 2008;14:399–405. - PubMed
-
- Habek M, Brinar VV, Hajnsek S. The association of multiple sclerosis and Hodgkin’s disease: the role of Epstein-Barr virus infection. Mult Scler. 2008;14:284–287. - PubMed
-
- Ehrlich Y, Baniel J. Late relapse of testis cancer. Urol Clin North Am. 2007;34:253–258. - PubMed
-
- International Germ Cell Cancer Collaborative Group (IGCCCG) a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol. 1997;15:594–603. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources